{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:34:59Z","timestamp":1707525299636},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,14]]},"DOI":"10.7759\/cureus.45217","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T15:16:33Z","timestamp":1694704593000},"source":"Crossref","is-referenced-by-count":0,"title":["Chronic Ulcer on the Tongue as a Manifestation of Histoplasmosis During Anti-tumor Necrosis Factor-Alpha (TNF-\u237a) Inhibitor Therapy for Psoriasis"],"prefix":"10.7759","author":[{"given":"Iris","family":"Harrison","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahtab","family":"Forouzandeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiran","family":"Motaparthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"Saurat JH","year":"2008","unstructured":"Saurat JH, Stingl G, Dubertret L, et al.. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008, 158:558-66. 10.1111\/j.1365-2133.2007.08315.x","journal-title":"Br J Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2004.02571.x","article-title":"Infectious complications of tumor necrosis factor-alpha antagonists","volume":"44","author":"Bakleh M","year":"2005","unstructured":"Bakleh M, Tleyjeh I, Matteson EL, Osmon DR, Berbari EF. Infectious complications of tumor necrosis factor-alpha antagonists. Int J Dermatol. 2005, 44:443-8. 10.1111\/j.1365-4632.2004.02571.x","journal-title":"Int J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.01.875","article-title":"Proactive infectious disease approach to dermatologic patients who are taking tumor necrosis factor-alfa antagonists: Part I. Risks associated with tumor necrosis factor-alfa antagonists","volume":"71","author":"Chirch LM","year":"2014","unstructured":"Chirch LM, Cataline PR, Dieckhaus KD, Grant-Kels JM. Proactive infectious disease approach to dermatologic patients who are taking tumor necrosis factor-alfa antagonists: Part I. Risks associated with tumor necrosis factor-alfa antagonists. J Am Acad Dermatol. 2014, 71:1.e1-8; quiz 1.e8-9, 10. 10.1016\/j.jaad.2014.01.875","journal-title":"J Am Acad Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004732","article-title":"Worldwide phylogenetic distributions and population dynamics of the genus histoplasma","volume":"10","author":"Teixeira Mde M","year":"2016","unstructured":"Teixeira Mde M, Patan\u00e9 JS, Taylor ML, et al.. Worldwide phylogenetic distributions and population dynamics of the genus histoplasma. PLoS Negl Trop Dis. 2016, 10:e0004732. 10.1371\/journal.pntd.0004732","journal-title":"PLoS Negl Trop Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1086\/648724","article-title":"Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy","volume":"50","author":"Hage CA","year":"2010","unstructured":"Hage CA, Bowyer S, Tarvin SE, Helper D, Kleiman MB, Wheat LJ. Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy. Clin Infect Dis. 2010, 50:85-92. 10.1086\/648724","journal-title":"Clin Infect Dis"},{"key":"ref6","article-title":"Atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy","volume":"9","author":"Kamili Qu","year":"2010","unstructured":"Kamili Qu, Menter A. Atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy. J Drugs Dermatol. 2010, 9:57-60.","journal-title":"J Drugs Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20153545","article-title":"Cutaneous histoplasmosis as a complication after anti-TNF use--case report","volume":"90","author":"Zattar GA","year":"2015","unstructured":"Zattar GA, Cardoso F, Nakandakari S, Soares CT. Cutaneous histoplasmosis as a complication after anti-TNF use--case report. An Bras Dermatol. 2015, 90:104-7. 10.1590\/abd1806-4841.20153545","journal-title":"An Bras Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ299","article-title":"Histoplasmosis complicating tumor necrosis factor-\u03b1 blocker therapy: a retrospective analysis of 98 cases","volume":"61","author":"Vergidis P","year":"2015","unstructured":"Vergidis P, Avery RK, Wheat LJ, et al.. Histoplasmosis complicating tumor necrosis factor-\u03b1 blocker therapy: a retrospective analysis of 98 cases. Clin Infect Dis. 2015, 61:409-17. 10.1093\/cid\/civ299","journal-title":"Clin Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-2-200207160-00008","article-title":"Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS","volume":"137","author":"Johnson PC","year":"2002","unstructured":"Johnson PC, Wheat LJ, Cloud GA, et al.. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med. 2002, 137:105-9. 10.7326\/0003-4819-137-2-200207160-00008","journal-title":"Ann Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-021-00581-7","article-title":"Reintroduction of immunosuppressive medications in pediatric rheumatology patients with histoplasmosis: a case series","volume":"19","author":"Brown RA","year":"2021","unstructured":"Brown RA, Barbar-Smiley F, Yildirim-Toruner C, Ardura MI, Ardoin SP, Akoghlanian S. Reintroduction of immunosuppressive medications in pediatric rheumatology patients with histoplasmosis: a case series. Pediatr Rheumatol Online J. 2021, 19:84. 10.1186\/s12969-021-00581-7","journal-title":"Pediatr Rheumatol Online J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics9030077","article-title":"Prevalence of oral Lesions and correlation with intestinal symptoms of inflammatory bowel disease: a systematic review","volume":"9","author":"Lauritano D","year":"2019","unstructured":"Lauritano D, Boccalari E, Di Stasio D, Della Vella F, Carinci F, Lucchese A, Petruzzi M. Prevalence of oral Lesions and correlation with intestinal symptoms of inflammatory bowel disease: a systematic review. Diagnostics (Basel). 2019, 9:77. 10.3390\/diagnostics9030077","journal-title":"Diagnostics (Basel)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-014-8450-y","article-title":"The clinical features of sarcoidosis: a comprehensive review","volume":"49","author":"Judson MA","year":"2015","unstructured":"Judson MA. The clinical features of sarcoidosis: a comprehensive review. Clin Rev Allergy Immunol. 2015, 49:63-78. 10.1007\/s12016-014-8450-y","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2004.01896.x","article-title":"Clinicopathologic features of ulcerative-atrophic sarcoidosis","volume":"43","author":"Yoo SS","year":"2004","unstructured":"Yoo SS, Mimouni D, Nikolskaia OV, Kouba DJ, Sauder DN, Nousari CH. Clinicopathologic features of ulcerative-atrophic sarcoidosis. Int J Dermatol. 2004, 43:108-12. 10.1111\/j.1365-4632.2004.01896.x","journal-title":"Int J Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2004.02.030","article-title":"The antineutrophil cytoplasmic antibody-associated vasculitides","volume":"117","author":"Seo P","year":"2004","unstructured":"Seo P, Stone JH. The antineutrophil cytoplasmic antibody-associated vasculitides. Am J Med. 2004, 117:39-50. 10.1016\/j.amjmed.2004.02.030","journal-title":"Am J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjoto.2012.12.016","article-title":"Sarcoidosis-like granulomatosis of the hypopharynx as a complication of anti-TNF therapy","volume":"34","author":"Christoforidou A","year":"2013","unstructured":"Christoforidou A, Goudakos J, Bobos M, Lefkaditis E, Vital V, Markou K. Sarcoidosis-like granulomatosis of the hypopharynx as a complication of anti-TNF therapy. Am J Otolaryngol. 2013, 34:268-72. 10.1016\/j.amjoto.2012.12.016","journal-title":"Am J Otolaryngol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s12105-017-0804-3","article-title":"Oral pyoderma gangrenosum: diagnosis, treatment and challenges: a systematic review","volume":"11","author":"Bissonnette C","year":"2017","unstructured":"Bissonnette C, Kauzman A, Mainville GN. Oral pyoderma gangrenosum: diagnosis, treatment and challenges: a systematic review. Head Neck Pathol. 2017, 11:427-41. 10.1007\/s12105-017-0804-3","journal-title":"Head Neck Pathol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/178354-chronic-ulcer-on-the-tongue-as-a-manifestation-of-histoplasmosis-during-anti-tumor-necrosis-factor-alpha-tnf--inhibitor-therapy-for-psoriasis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:05:12Z","timestamp":1707509112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/178354-chronic-ulcer-on-the-tongue-as-a-manifestation-of-histoplasmosis-during-anti-tumor-necrosis-factor-alpha-tnf--inhibitor-therapy-for-psoriasis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.45217","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,14]]}}}